<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03914820</url>
  </required_header>
  <id_info>
    <org_study_id>IRFMN-CRC- 7813</org_study_id>
    <secondary_id>2019-001437-14</secondary_id>
    <nct_id>NCT03914820</nct_id>
  </id_info>
  <brief_title>Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Colorectal Carcinoma. CHECK Study.</brief_title>
  <acronym>CHECK</acronym>
  <official_title>Prophylactic Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC CO2) Versus Standard Surgery in Colorectal Carcinoma at High Risk Peritoneal Carcinomatosis. Short and Long-term Outcomes. A Collaborative Randomized Controlled Trial of: ACOI, FONDAZIONE AIOM, SIC, SICE, SICO. CHECK STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III randomized, multicenter study with two different arm:&#xD;
&#xD;
        -  experimental: prophylactic surgery plus HIPEC CO2 performed with mitomycin&#xD;
&#xD;
        -  comparator: standard surgery Adjuvant treatment after surgery is mandatory except for&#xD;
           documented cases of non-eligibility.&#xD;
&#xD;
      Patient will be randomized in a 1:1 ratio. Randomization will be done during surgery if the&#xD;
      total resection of tumour will be reached and will use a stratification procedure based on&#xD;
      center&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III randomized, multicenter study with two different arm:&#xD;
&#xD;
        -  experimental: prophylactic surgery plus HIPEC CO2 performed with mitomycin&#xD;
&#xD;
        -  comparator: standard surgery Adjuvant treatment after surgery is mandatory except for&#xD;
           documented cases of non-eligibility.&#xD;
&#xD;
      Patient will be randomized in a 1:1 ratio. Randomization will be done during surgery if the&#xD;
      total resection of tumour will be reached and will use a stratification procedure based on&#xD;
      center&#xD;
&#xD;
      The HIPEC CO2 regimen will be as reported below:&#xD;
&#xD;
      mitomycin: (total dose of 35 mg/mq, physiologic solution 0.9%) administrated 50% at time 0&#xD;
      from start of HIPEC CO2 treatment (17.5 mg/mq), 25% (8.8 mg/mq) after 30 minutes and the last&#xD;
      dose 25% after 60 minutes. Recommended temperature for HIPEC treatment is 41-42 °C for 90&#xD;
      minutes.&#xD;
&#xD;
      Adjuvant treatment consists of a 6 months chemotherapy after surgery. It is possible to&#xD;
      choose between Oxaliplatin, Capecitabine (XELOX) or Oxaliplatin, Fluorouracil, Leucovorin&#xD;
      (FOLFOX-4) Patients affected by CRC at high risk of developing peritoneal carcinomatosis will&#xD;
      be randomized in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a phase III randomized, multicenter study with two different arm:&#xD;
experimental: prophylactic surgery plus HIPEC CO2 performed with mitomycin&#xD;
comparator: standard surgery</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local recurrence free survival (LRFS)</measure>
    <time_frame>This outcome measure will be assess approximately 3 years after the last patient enrolled</time_frame>
    <description>The primary efficacy endpoint is LRFS defined as the time from randomization to the date of first local relapse, peritoneal carcinomatosis or death for any cause, whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>This outcome measure will be assess approximately 3 years after the last patient enrolled</time_frame>
    <description>Disease Free Survival (DFS) DFS is defined as the time from randomization to the date of first local relapse, distant relapse, peritoneal carcinomatosis or death for any cause, whichever comes first.&#xD;
OS is defined as the time from randomization to death for any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>This outcome measure will be assessed approximately 3 years after the last patient enrolled</time_frame>
    <description>death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of post-surgery complication</measure>
    <time_frame>This outcome measure will be assessed approximately 3 years after the last patient enrolled</time_frame>
    <description>any type of complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morbidity</measure>
    <time_frame>This outcome measure will be assessed approximately 3 years after the last patient enrolled</time_frame>
    <description>evaluated during and after surgery, graded according to the NCI-CTAE version 4.03 for AE related to chemotherapy and according to Clavien Dindo for surgery complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of surgery</measure>
    <time_frame>This outcome measure will be assessed approximately 3 years after the last patient enrolled</time_frame>
    <description>timing of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients performing the adjuvant chemotherapy.</measure>
    <time_frame>This outcome measure will be assessed approximately 3 years after the last patient enrolled</time_frame>
    <description>patients performing the adjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospitalization</measure>
    <time_frame>This outcome measure will be assessed approximately 3 years after the last patient enrolled</time_frame>
    <description>length of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality at 30 and 90 days from surgery</measure>
    <time_frame>This outcome measure will be assessed approximately 3 years after the last patient enrolled</time_frame>
    <description>mortality at 30 and 90 days from surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prophylactic surgery plus HIPEC CO2 performed with mitomycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard surgey without HIPEC CO2</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HIPEC CO2</intervention_name>
    <description>Prophylactic surgery plus HIPEC CO2 performed with mitomycin</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard surgery</intervention_name>
    <description>Standard surgery without HIPEC CO2</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically documented colorectal adenocarcinoma eligible for R0,&#xD;
&#xD;
               1. Presurgical or intraoperative stage T4a or T4b primary tumour (TNM 8 th)&#xD;
&#xD;
               2. Urgent presentation: perforation without purulent generalized peritonitis or&#xD;
                  fecal peritonitis&#xD;
&#xD;
               3. Peritumoral minimal peritoneal carcinomatosis: limited peritoneal disease in&#xD;
                  close proximity to the primary tumour, that may be removed en bloc&#xD;
&#xD;
               4. Ovarian metastases (Krukenberg tumor)&#xD;
&#xD;
          2. Age ≥ 18 and ≤75 years&#xD;
&#xD;
          3. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Distant metastatic disease (even if limited and completely resected)&#xD;
&#xD;
          2. History of tumour diagnosed in the 3 years before entering the study, except for&#xD;
             topical and healed pathologies that do not need further treatment (e.g. non-melanoma&#xD;
             skin carcinomas, superficial bladder carcinomas or in situ carcinoma of the breast or&#xD;
             cervix).&#xD;
&#xD;
          3. Psychological, family or social conditions which may negatively affect the treatment&#xD;
             and follow-up protocol.&#xD;
&#xD;
          4. Poor general conditions (ECOG &gt; 2).&#xD;
&#xD;
          5. Impaired cardiac function (history of congestive heart failure or FE &lt;40%). Clinically&#xD;
             significant cardiovascular disease: cerebral vascular accident/stroke (&lt;6 months prior&#xD;
             to enrolment), myocardial infarction (&lt;6 months prior to enrolment), unstable angina,&#xD;
             congestive heart failure (New York Heart Association Classification Class &gt; II or&#xD;
             serious uncontrolled cardiac Arythmia requiring medication&#xD;
&#xD;
          6. Impaired renal function (creatinine&gt; 1.5 upper limit of normal or creatinine clearance&#xD;
             &lt;60 mL / min)&#xD;
&#xD;
          7. Impaired hepatic function (AST, ALT &gt;2.5 upper limit of normal, bilirubin&gt; 1.5 upper&#xD;
             limit of normal)&#xD;
&#xD;
          8. Impaired hematopoietic function (leucocytes &lt;4000 / mm3, neutrophils &lt;1500 / mm3,&#xD;
             platelets &lt;100000 / mm3)&#xD;
&#xD;
          9. Impaired pulmonary function (presence of COPD or other pulmonary restrictive&#xD;
             conditions with FEV1 &lt;50% or DLCO &lt;40% of normal age value).&#xD;
&#xD;
         10. Pregnancy&#xD;
&#xD;
         11. History or presence of other diseases, metabolic dysfunction, or clinical laboratory&#xD;
             finding giving reasonable suspicion of a disease or condition that contraindicates use&#xD;
             of HIPEC or chemotherapy or patient at high risk from treatment complications.&#xD;
&#xD;
         12. Chronic inflammatory bowel disease&#xD;
&#xD;
         13. Patients with acute bowel obstruction&#xD;
&#xD;
         14. Refusal to join the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Pacelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>fabio.pacelli@policlinicogemelli.it</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio Pacelli, MD</last_name>
    <phone>0039063015</phone>
    <phone_ext>7255</phone_ext>
    <email>fabio.pacelli@policlinicogemelli.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erica Rulli</last_name>
    <phone>0039023901</phone>
    <phone_ext>4684</phone_ext>
    <email>erica.rulli@marionegri.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Simone</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASP PO Sant'Elia</name>
      <address>
        <city>Caltanissetta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Ciaccio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Santa Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ULLS1 1 Dolomiti - Ospedale di Feltre</name>
      <address>
        <city>Feltre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale dell Angelo</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Ferrari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico di Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. A. Cardarelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Evangelico Betania</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Persiani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli Irccs Universita' Cattolica Del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Pacelli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer, HIPEC CO2, prophylactic surgery , mitomycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

